Publications by authors named "K Besien"
Article Synopsis
- Novel therapies like CAR-T, BTK inhibitors, and PD-1 inhibitors have transformed the treatment of aggressive B-cell lymphomas but can also lead to late side effects like second cancers and treatment failures.
- CAR-T therapy is now preferred over autologous transplant for recurrent diffuse large B-cell lymphoma, while autologous transplant remains important for certain relapses and CNS lymphoma consolidation.
- Allogeneic stem cell transplants are generally reserved for cases where autologous transplants fail, offering lower relapse rates but higher complications, highlighting the need for careful patient selection and treatment timing.
Article Synopsis
- The SIERRA trial aimed to improve outcomes for older patients with relapsed or refractory acute myeloid leukemia (RR AML) by comparing a new treatment, I-apamistamab, against standard care before bone marrow transplant.
- The study involved 153 patients, with results showing a significantly higher durable complete remission (dCR) rate of 17.1% for the I-apamistamab group compared to 0% for the conventional care group.
- Although the overall survival rates were similar between the two groups, the I-apamistamab regimen exhibited more promise for achieving long-lasting remission with similar levels of severe side effects.
Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients with MF (18 chronic phase, 2 accelerated phase, and 1 blast phase) were treated with a 10-day schedule of subcutaneous decitabine at 0.3 mg/kg per day.
View Article and Find Full Text PDFDespite the established potentially curative role of allogeneic hematopoietic cell transplantation (allo-HCT) in managing myelofibrosis (MF), the choice of alternative donors for patients lacking matched donors remains a challenge, and the optimal graft source in this disease entity continues to be an ongoing debate. We aimed to evaluate the impact of donor type: umbilical cord blood transplant supported with CD34+ selected haploidentical donor (haplo-cord) versus adult matched related donor (MRD) and matched unrelated donor (MUD) in 40 adult patients with primary or secondary MF, including those progressing to accelerated phase (AP) or blast phase (BP), who underwent their first allo-HCT. The primary objective of this study was to analyze the impact of stem cell source on primary endpoints of overall survival (OS), graft-versus-host disease, and non-relapse mortality (NRM).
View Article and Find Full Text PDF